Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer (Businesswire) - Oct 3, 2023 - "Kezar anticipates initial data from its KZR-261 Phase 1 clinical trial in 2024....Kezar is also evaluating its Phase 1 clinical trial of KZR-261 in solid tumors and expects to reduce the number of planned expansion cohorts to conserve cash resources while it continues to evaluate safety and biologic activity in the ongoing trial."
Clinical protocol • P1 data • Solid Tumor
|